Clinical Trials Logo

Hematologic Neoplasms clinical trials

View clinical trials related to Hematologic Neoplasms.

Filter by:

NCT ID: NCT04454723 Completed - Clinical trials for Hematologic Malignancy

Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice

PalliaQOL
Start date: August 14, 2020
Phase: N/A
Study type: Interventional

The purpose of this pilot research study is to evaluate the effectiveness of blood and platelet transfusions in improving symptoms and quality of life of patients enrolled in hospice.

NCT ID: NCT04425642 Completed - Clinical trials for Hematologic Malignancy

Effects of Parenteral Nutrition in HSCT

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

Nutritional therapy implementation in hematopoietic stem cell transplantation (HSCT) have undergone changes recently due to new conditioning regimen and graft versus disease prophylaxis, novel enteral and parenteral nutrition solutions: the value of enteral nutrition is increasing, the indications for parenteral nutrition are becoming more strict. The study aims to identify the role of parenteral nutrition in the context of rapidly changing supportive care approaches in HSCT

NCT ID: NCT04419623 Completed - Cancer Clinical Trials

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Start date: July 9, 2020
Phase: Phase 1
Study type: Interventional

This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.

NCT ID: NCT04389541 Completed - Clinical trials for Advanced Solid Tumors or Hematologic Malignancies

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

INFINITY
Start date: April 17, 2020
Phase:
Study type: Observational [Patient Registry]

The retrospective cohort study INFINITY will be an instrument to analyze the current practice of precision oncology in the real-world setting. It will provide insight into real-world biomarker-directed treatment of cancer patients not eligible for standard therapies. The study will retrospectively collect medical records' data of patients who received a targeted treatment based on a potentially actionable alteration or biomarker identified by molecular diagnostics. Data of deceased patients will be included. The study will analyze how molecular test results guided clinical decision making. The compiled treatment and outcome data will be a valuable resource to analyze the use and effectiveness of targeted therapy approaches in biomarker-defined and entity-defined subpopulations of cancer patients. These signals might generate new insights and foster progress of targeted cancer treatment. The associated biomarker profiling module aims to set up a decentral biobank for future research on molecular alterations or central re-testing.

NCT ID: NCT04303091 Completed - Multiple Myeloma Clinical Trials

The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients

Start date: March 2, 2018
Phase: N/A
Study type: Interventional

Although physical activity (PA) is commonly used to manage symptoms and enhance quality of life (QOL) in cancer survivors, relatively little is known regarding the benefits in advanced multiple myeloma (MM). The primary aims of the Physical Activity in Advanced Cancer Treatment (PAACT) intervention were to examine (1) program feasibility and (2) potential impact on patient outcomes. It is hypothesized that an exercise intervention will be feasible and potentially impactful.

NCT ID: NCT04282343 Completed - Clinical trials for Chronic Lymphocytic Leukemia

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Start date: February 25, 2020
Phase: N/A
Study type: Interventional

This phase II trial studies how well the DIScussion of COst (DISCO) application (app) works in improving financial outcomes in patients with hematologic cancer. The DISCO app is an electronic, highly scalable and tailorable education and communication intervention that may help researchers learn more about improving how patients and oncologists discuss cancer treatment costs

NCT ID: NCT04279405 Completed - Clinical trials for Mantle Cell Lymphoma

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Start date: June 15, 2020
Phase: Phase 1
Study type: Interventional

Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.

NCT ID: NCT04264767 Completed - Cancer Clinical Trials

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Start date: April 17, 2019
Phase:
Study type: Observational

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

NCT ID: NCT04236063 Completed - Lymphoma Clinical Trials

Rehabilitation Needs of the Malaysian Haematological Cancer Survivors

Start date: July 15, 2019
Phase:
Study type: Observational [Patient Registry]

Many cancers are being treated more effectively nowadays due to the raised awareness and early detection as well as advancement in researches and technology. Despite the rising number of cancer survivors in the coming years, these survivors are still plagued by the poor quality of life due to physical and psychological impairment. According to the National Cancer Registry Report from 2007-2011, haematological cancer is one of the ten most common cancers in Malaysian population. Many haematological cancer survivors in Malaysia are reportedly having poor quality of life due to multiple physical and emotional impairments which leads to further disability in life. It is thus an important effort to identify the rehabilitation needs in these cancer survivors to implement alternatives to improve the disease outcome through cancer rehabilitation.

NCT ID: NCT04235153 Completed - Chemotherapy Effect Clinical Trials

CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients

CANUT-QVA
Start date: January 9, 2020
Phase:
Study type: Observational

Cancer patients are at high risk of undernutrition, which is generally more pronounced for solid tumours (upper digestive tract, Ear Nose and Throat (ENT), bronchial tubes). This undernutrition leads to major weight loss and cachexia, and may represent the first sign of a call for a diagnosis of cancer. Cancer-related undernutrition is multi-factorial origins and has multiple consequences. Chemotherapy treatments can induce various adverse effects in patients, including sensory disturbances at the beginning of treatment in addition to disturbances that may already be present before any treatment. The alteration of taste and odour, observed in 86% of patients, can induce a change in food preferences, promote the development of aversions, and therefore, lead to a significant reduction in the pleasure of eating. Loss of appetite, decreased food intake and the development of aversions to certain foods are situations experienced by a large proportion of patients treated with chemotherapy. The assessment of taste disorders in patients treated with chemotherapy is established through the use of questionnaires, interviews and taste tests. Changes in the perception and identification of salty, sweet, bitter and sour flavours are common in patients treated with chemotherapy. As regards food products, patients report developing olfactory hypersensitivity mainly for food of animal origin, in particular for odours of fish, frying, cheese and eggs. The CANUT project aims to study the effect of pathology and chemotherapy on gustatory and olfactory mechanisms, and in particular on interindividual differences in the perception and appreciation of food. In order to monitor the evolution of patients' eating habits over time, the diet-related quality of life questionnaire (CANUT-QVA) was constructed from items selected from the Well-being related to Food questionnaire (WELLBFQ) after eliminating questions that were too general or expressed in terms of importance to use perception-related responses as a priority. After this part, an evaluation of the 9 dimensions of the CANUT-QVA questionnaire will be performed.